Search

Your search keyword '"Mornex, F."' showing total 1,152 results
Start Over Author "Mornex, F."
1,152 results on '"Mornex, F."'

105. Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non–Small-Cell Lung Cancer Patients

Author

Ramaekers, Bram L.T., Joore, Manuela A., Lueza, Béranger, Bonastre, Julia, Mauguen, Audrey, Pignon, Jean-Pierre, Le Pechoux, Cecile, De Ruysscher, Dirk K.M., Grutters, Janneke P.C., Arriagada, R., Bae, K., Ball, D., Baumann, M., Behrendt, K., Belani, C.P., Beresford, J., Bishop, J., Bonner, J.A., Choy, H., Dahlberg, S.E., De Ruysscher, D., Dische, S., Fournel, P., Koch, R., Le Péchoux, C., Mandrekar, S.J., Mauguen, A., Mornex, F., Nankivell, M., Nelson, G., Parmar, M.K., Paulus, R., Pignon, J.P., Saunders, M.I., Sause, W., Schild, S.E., Turrisi, A.T., and Zajusz, A.

Published
2013
Full Text
View/download PDF

120. Lung Cancer

Author

Van Houtte, P., primary, Mornex, F., additional, Loubeyre, P., additional, Rocmans, P., additional, and Vaylet, F., additional

Published
2004
Full Text
View/download PDF

121. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the committee for medicinal products for human use (chmp)

Author

Peters, S. Dafni, U. Boyer, M. De Ruysscher, D. Faivre-Finn, C. Felip, E. Garrido, P. Girard, N. Guckenberger, M. Haanen, J. Le Pechoux, C. Mornex, F. Ozsahin, M. Paz-Ares, L. Planchard, D. Raben, D. Ramalingam, S. Reck, M. Smit, E. Stahel, R. Stenzinger, A. Swanton, C. Vallone, S. Garassino, M.C.

Published
2019

122. Prophylactic cranial irradiation in stage IV small cell lung cancer: 5 Selection of patients amongst European IASLC and ESTRO experts

Author

Putora, P. M., Glatzer, M., Belderbos, J., Besse, B., Blackhall, F., Califano, R., Cappuzzo, F., Marinis, F., Dziadziuszko, R., Felip, E., Faivre-Finn, C., Früh, M., Garrido, P., Le Pechoux, C., Mcdonald, F., Nestle, U., Novello, S., O‘Brien, M., Paz Ares, L., Peeters, S., Pöttgen, C., Ramella, S., Reck, M., Slotman, B., Troost, E. G. C., Houtte, P. V., Westeel, V., Widder, J., Mornex, F., and Ruysscher, D.

Subjects
Small cell lung cancer, Expert opinion, IASLC, PCI, ESTRO, Stage IV
Abstract

Background: Due to conflicting results between major trials the role of prophylactic cranial irradiation (PCI) in stage IV small cell lung cancer (SCLC) is controversial. Methods: We obtained a list of 13 European experts from both the European Society for Therapeutic Radiation Oncology (ESTRO) and the International Association for the Study of Lung Cancer (IASLC). The strategies in decision making for PCI in stage IV SCLC were collected. Decision trees were created representing these strategies. Analysis of consensus was performed with the objective consensus methodol-ogy. Results: The factors associated with the recommendation for the use of PCI included the fitness of the patient, young age and good response to chemotherapy. PCI was recommended by the majority of experts for non-elderly fit patients who had at least a partial response (PR) to chemotherapy (for complete remission (CR): 85% of radiation oncologists and 69% of medical oncologists, for partial remission: 85% of radiation oncol- ogists and 54% of medical oncologists). For patients with stable disease after chemotherapy, PCI was rec- ommended by 6 out of 13 (46%) radiation oncologists and only 3 out of 13 medical oncologists (23%). For elderly fit patients with CR, a majority recommended PCI (62%) and no consensus was reached for patients with PR. Conclusion: European radiation and medical oncologists specializing in lung cancer recommend PCI in selected patients and restrict its use primarily to fit, non-elderly patients who responded to chemotherapy.

Published
2019

126. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

Author

Putora, P. M., Glatzer, M., Ruysscher, D., Faivre-Finn, C., Belderbos, J., Besse, B., Blackhall, F., Califano, R., Cappuzzo, F., Marinis, F., Dziadiuszko, R., Felip, E., Früh, M., Garrido, P., Le Pechoux, C., Mcdonald, F., Nestle, U., Novello, S., Brien, M. O., Paz Ares, L., Peeters, S., Pöttgen, S., Ramella, S., Reck, M., Troost, E. G. C., Houtte, P., Westeel, V., Widder, J., Mornex, F., Slotman, B. J., Putora, P. M., Glatzer, M., Ruysscher, D., Faivre-Finn, C., Belderbos, J., Besse, B., Blackhall, F., Califano, R., Cappuzzo, F., Marinis, F., Dziadiuszko, R., Felip, E., Früh, M., Garrido, P., Le Pechoux, C., Mcdonald, F., Nestle, U., Novello, S., Brien, M. O., Paz Ares, L., Peeters, S., Pöttgen, S., Ramella, S., Reck, M., Troost, E. G. C., Houtte, P., Westeel, V., Widder, J., Mornex, F., and Slotman, B. J.

Abstract

Background: The role of consolidative thoracic radiotherapy (TRT) in stage IV small cell lung cancer (SCLC) is not uniformly accepted. Methods: We obtained a list of 13 European medical oncologists from the International Association for the Study of Lung Cancer (IASLC) and 13 European radiation oncologists from the European Society for Therapeutic Radiation Oncology (ESTRO). The strategies in decision making for TRT in stage IV SCLC were collected. Decision trees were created representing these strategies. Frequencies of recommending TRT were analysed for various parameter combinations based on the objective consensus methodology. Results: The factors associated with the recommendation for TRT included fitness of the patient, limited extrathoracic tumour burden, initial bulky thoracic disease and response to chemotherapy. The highest consensus for TRT was in fit patients with limited extrathoracic tumour burden and initial bulky disease with either a complete extrathoracic response or partial thoracic response (92% recommend TRT). For these patients the recommendations were the same for medical and radiation oncologists. In the setting of partial response (intra- and extra-thoracically) without initial bulky thoracic disease radiation oncologists were more likely to recommend TRT than medical oncologists. For unfit patients or for patients with poor overall response to chemotherapy, the majority did not recommend TRT. Conclusion: European radiation and medical oncologists specializing in lung cancer recommend TRT in selected patients with stage IV SCLC and restrict its use primarily to fit patients who responded to chemotherapy with limited extrathoracic tumour burden.

Published
2019

128. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1*

Author

Robinet, G., Thomas, P., Breton, J. L., Léna, H., Gouva, S., Dabouis, G., Bennouna, J., Souquet, P. J., Balmes, P., Thiberville, L., Fournel, P., Quoix, E., Riou, R., Rebattu, P., Pérol, M., Paillotin, D., and Mornex, F.

Published
2001

133. Le taux d’apoptose lymphocytaire radio-induit CD8 prédicteur de la toxicité pelvienne après radiothérapie prostatique : résultats de l’étude prospective multicentrique française

Author

Azria, D., primary, Créhange, G., additional, Castan, F., additional, Belkacemi, Y., additional, Lagrange, J., additional, Nguyen, T., additional, Chapet, O., additional, Mornex, F., additional, Noel, G., additional, Lartigau, E., additional, Pasquier, D., additional, Clippe, S., additional, Hennequin, C., additional, Gourgou, S., additional, Brengues, M., additional, Fenoglietto, P., additional, Farcy-Jacquet, M., additional, and Ozsahin, M., additional

Published
2019
Full Text
View/download PDF

134. P2.18-01 A Multicenter, Double-Blind, Randomized, Controlled Study of Bintrafusp Alfa (M7824) in Unresectable Stage III NSCLC

Author

Vokes, E., primary, Adjei, A., additional, Ahn, M., additional, Barlesi, F., additional, Felip, E., additional, Garon, E., additional, Grenga, I., additional, Koenig, A., additional, Martin, C., additional, Mok, T., additional, Mornex, F., additional, Munshi, N., additional, Raben, D., additional, Robinson, C., additional, and Paz-Ares, L., additional

Published
2019
Full Text
View/download PDF

135. First real life data on durvalumab after definitive concomitant chemoradiotherapy (cCRT) in unresectable stage (St) III non-small cell lung cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) temporary authorization of use (ATU)

Author

Avrillon, V., primary, Bota Ouchlif, S., additional, Merle, P., additional, Pichon, E., additional, Stancu, A.T., additional, Chouaid, C., additional, Sire, C., additional, Boudabous, H., additional, Lagrange, A., additional, Sabatini, M., additional, Eberst, G., additional, Boisselier, P., additional, Gourion, A., additional, Lion, A., additional, Lahouegue, A., additional, Belkhiria, K., additional, de La Porte, I., additional, Urbieta, M., additional, Mornex, F., additional, and Girard, N., additional

Published
2019
Full Text
View/download PDF

136. OC-0498 Results of the prospective trial evaluating radiation-induced lymphocyte apoptosis and prostate RT

Author

Azria, D., primary, Crehange, G., additional, Castan, F., additional, Schwartz, E., additional, Belkacemi, Y., additional, Lagrange, J., additional, NGuyen, T., additional, Chapet, O., additional, Mornex, F., additional, Noel, G., additional, Lartigau, E., additional, Pasquier, D., additional, Clippe, S., additional, Hennequin, C., additional, Gourgou, S., additional, Brengues, M., additional, Fenoglietto, P., additional, Farcy-Jacquet, M., additional, and Ozsahin, E., additional

Published
2019
Full Text
View/download PDF

138. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Author

Peters, S., primary, Dafni, U., additional, Boyer, M., additional, De Ruysscher, D., additional, Faivre-Finn, C., additional, Felip, E., additional, Garrido, P., additional, Girard, N., additional, Guckenberger, M., additional, Haanen, J., additional, Le Pechoux, C., additional, Mornex, F., additional, Ozsahin, M., additional, Paz-Ares, L., additional, Planchard, D., additional, Raben, D., additional, Ramalingam, S., additional, Reck, M., additional, Smit, E., additional, Stahel, R., additional, Stenzinger, A., additional, Swanton, C., additional, Vallone, S., additional, and Garassino, M.C., additional

Published
2019
Full Text
View/download PDF

150. Hafnium Oxide Nanoparticles Activated By Radiation Therapy: An Innovative Approach for the Treatment of Liver Cancers

Author

Chajon Rodriguez, E., primary, Pracht, M., additional, De Baere, T., additional, Nguyen, T.V.F., additional, Bronowicki, J.P., additional, Vendrely, V., additional, Baumann, A.S., additional, Croisé-Laurent, V.V., additional, Rio, E., additional, Rolland, Y., additional, Le Sourd, S., additional, Gustin, P., additional, Perret, C., additional, Mornex, F., additional, Peiffert, D., additional, Merle, P., additional, and Deutsch, E., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results